1Ando S,Kinmra H,Iwai N. Optimal combination of seven tumor markers in prediction of patient with non-small cell lung cancer[J].Anticancer Research,2001,(4B):3085-3092.
2Shi HZ,Liang QL,Jiang J. Diagnostic value of carcinoembryonic antigen in malignant pleural effusion:a meta-analysis[J].Respirology,2008,(04):518-527.doi:10.1111/j.1440-1843.2008.01291.x.
3Fuhrman C,Duche JC,Chouaid C. Use of tumor markers for differential diagnosis of mesothelima and secondary pleura malignancies[J].Clinical Biochemistry,2000,(05):405-410.
4Molina R,Filella X,Jo J. CA125 in biological fluids[J].Int J BiolMarkers,1998,(04):224-230.
5Westfall DE,Fan X,Marchevsky AM. Evidence-based guidelines to optimize the selection of antibody panels in cytopathology:pleural effusions with malignant epithelioid cells[J].Diagn Cyropathol,2010,(01):9-14.
6Creaney J,van Bruggen I,Hof M. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma[J].Chest,2007,(04):1239-1246.
7Grigoriu BD,Grigoriu C,Chahine B. Clinical utility of diagnostic markers for malignant pleural mesothelioma[J].Monaldi Archives of Chest Disease,2009,(02):31-38.
8Li CS,Cheng BC,Ge W. Clinical value of cYFRA21-1,NSE,CA 15-3,CA 19-9 and CA 125 assay in the elderly patients with pleural effusions[J].Clinical Practice,2007,(03):444-448.
9Liang QL,Shi HZ,Qin XJ. Diagnostic accuracy of tumour markers for malignant pleural effusion:a meta-analysis[J].Thorax,2008,(01):35-41.
10van der Bij S,Schaake E,Koffijberg H. Markers for the non-invasive diagnosis of mesothelioma:a systematic review[J].British Journal of Cancer,2011,(08):1325-1333.
